A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Roche

Status and phase: Completed; Phase 3

Conditions: Breast Cancer

Treatments: Drug: trastuzumab emtansine; Drug: trastuzumab

Study type: Interventional

Funder types: Other; NETWORK; Industry

Identifiers

NCT01772472

2012-002018-37 (EudraCT Number)

BO27938

Details and patient eligibility

About

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.

Enrollment: 1,487 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient, >/= 18 years of age
• HER2-positive breast cancer
• Histologically confirmed invasive breast carcinoma
• Clinical stage T1-4/N0-3/M0 at presentation (patients with T1a/bN0 tumors will not be eligible)
• Completion of preoperative systemic chemotherapy and HER2-directed treatment consisting of at least 6 cycles of chemotherapy with a total duration of at least 16 weeks, including at least 9 weeks of trastuzumab and at least 9 weeks of taxane-based therapy
• Adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes as specified in protocol
• Pathological evidence of residual invasive carcinoma in the breast or axillary lymph nodes following completion of preoperative therapy
• An interval of no more than 12 weeks between the date of surgery and the date of randomization
• Known hormone-receptor status
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Adequate hematologic, renal and liver function
• Screening Left ventricular ejection fraction (LVEF) >/= 50% on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) after receiving neoadjuvant chemotherapy and no decrease in LVEF by more than 15% absolute points from the pre-chemotherapy LVEF. Or, if pre-chemotherapy LVEF was not assessed, the screening LVEF must be >/= 55% after completion of neoadjuvant chemotherapy.
• For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 7 months after the last dose of study drug
• Documentation of hepatitis B virus and hepatitis C virus serology is required

Exclusion criteria

• Stage IV (metastatic) breast cancer
• History of any prior (ipsi- or contralateral breast cancer except lobular carcinoma in situ
• Evidence of clinically evident gross residual or recurrent disease following preoperative therapy and surgery
• Progressive disease during preoperative systemic therapy
• Treatment with any anti-cancer investigational drug within 28 days prior to commencing study treatment
• History of other malignancy within the last 5 years except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other non-breast malignancies with a similar outcome to those mentioned above
• Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons
• Current NCI CTCAE (Version 4.0) Grade >/= 2 peripheral neuropathy
• History of exposure to the following cumulative doses of anthracyclines: Doxorubicin > 240 mg/m2; Epirubicin or Liposomal Doxorubicin-Hydrochloride (Myocet®) > 480 mg/m2; For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m2
• Cardiopulmonary dysfunction as defined by protocol
• Prior treatment with trastuzumab emtansine
• Current severe, uncontrolled systemic disease
• Pregnant or lactating women
• Any known active liver disease, e.g. due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis
• Concurrent serious uncontrolled infections requiring treatment or known infection with HIV
• History of intolerance, including Grade 3 to 4 infusion reaction or hypersensitivity to trastuzumab or murine proteins or any components of the product

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,487 participants in 2 patient groups

Trastuzumab

Active Comparator group

Treatment:

Drug: trastuzumab

Trastuzumab emtansine

Experimental group

Treatment:

Drug: trastuzumab emtansine